MedTrace Logo

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

NCT02033902 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-09-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of Fycompa (Perampanel) as an add-on therapy in epilepsy patients aged greater than or equal to 12 years.

Conditions

Interventions

DRUG

Perampanel

Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-06
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • Austria
  • Belgium
  • Czechia
  • Israel
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02033902 on ClinicalTrials.gov